"We showed that fMRI using a special liver-specific contrast agent is able to non-invasively investigate liver function, enabling us to predict the development of liver-related complications such as ascites, internal bleeding and/or hepatic encephalopathy, as well as to estimate the risk for mortality" says the senior author of this study, Ahmed Ba-Ssalamah from MedUni Vienna's Department of Biomedical Imaging and Image-guided Therapy.
Magnetic resonance tracks the dynamics of the contrast agent in the liver
The contrast agent, gadoxetic acid, is injected via a peripheral vein. It is absorbed by the liver cells (hepatocytes) and eliminated via the bile ducts. Chronic inflammation of the liver tissue, for example due to viral hepatitis or fatty liver disease may lead to scarring (fibrosis/cirrhosis) of the organ, resulting in a reduction in the number of functioning hepatocytes and/or a decrease in cellular transporters responsible for the uptake of the contrast agent into hepatocytes. This ultimately leads to decreased contrast agent elimination from the liver. Radiation-free fMRI shows this liver cell damage as reduced brightness of the liver and delayed excretion of contrast agent in the bile ducts on serial imaging.
The functional liver imaging score determines severity and mortality risk
Based on three specific fMRI parameters, a Functional Liver Imaging Score (FLIS), ranging from 0 (worst liver function) to 6 (best liver function) points, is calculated. The study found that patients with more severe liver disease had a lower FLIS (0-3 points), and a 3.7 times higher risk to develop liver-related complications than patients with a high FLIS (4-6 points). Furthermore, patients with advanced chronic liver disease and a low FLIS (0-3 points) had a significantly higher risk for mortality.
These results, published in the top journal "Radiology", will now be verified in a multi-centre study. This follow-up study will also investigate the extent to which fMRI can replace invasive methods of assessing the severity of liver disease. "However, the FLIS, based on functional Magnetic Resonance Imaging using liver-specific contrast agents, may be already used for non-invasive assessment of liver function in daily clinical practice," says Ba-Ssalamah.
Interdisciplinary collaboration within MedUni Vienna's Research Cluster
The recent study is based on interdisciplinary collaboration between the Department of Biomedical Imaging and Image-guided Therapy and the Division of Gastroenterology and Hepatology at MedUni Vienna and falls within the remit of the Medical Imaging Research Cluster. There are five such research clusters at MedUni Vienna. More and more emphasis is being placed on basic and clinical research in these subjects. The other research clusters are for immunology, cancer, cardiovascular disease and medical neurosciences.
The Hepatic Hemodynamic Laboratory at the Division of Gastroenterology and Hepatology carries out more than 350 invasive portal pressure measurements and liver biopsies via the jugular vein. This makes the Vienna Hepatic Hemodynamic Lab one of the largest of its kind in the world and the second largest centre in Europe.
Does the Functional Liver Imaging Score Derived from Gadoxetic Acid–enhanced MRI Predict Outcomes in Chronic Liver Disease? Nina Bastati, Lucian Beer, Mattias Mandorfer, Sarah Poetter-Lang, Dietmar Tamandl, Yesim Bican, Michael Christoph Elmer, Henrik Einspieler, Georg Semmler, Benedikt Simbrunner, Michael Weber, Jacqueline C. Hodge, Federica Vernuccio, Claude Sirlin, Thomas Reiberger, Ahmed Ba-Ssalamah. https://pubs.rsna.org/doi/10.1148/radiol.2019190734